Apellis Pharmaceuticals Inc (NASDAQ: APLS) has experienced a decline in its stock price by -1.37 compared to its previous closing price of 17.52. However, the company has seen a fall of -9.62% in its stock price over the last five trading days. zacks.com reported 2025-05-08 that APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Is It Worth Investing in Apellis Pharmaceuticals Inc (NASDAQ: APLS) Right Now?
Moreover, the 36-month beta value for APLS is 0.69. Analysts have varying opinions on the stock, with 12 analysts rating it as a “buy,” 4 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for APLS is 104.61M and currently, short sellers hold a 27.50% of that float. On May 14, 2025, APLS’s average trading volume was 2.38M shares.
APLS’s Market Performance
APLS’s stock has seen a -9.62% decrease for the week, with a -11.02% drop in the past month and a -39.43% fall in the past quarter. The volatility ratio for the week is 6.81%, and the volatility levels for the past 30 days are at 5.69% for Apellis Pharmaceuticals Inc The simple moving average for the last 20 days is -5.59% for APLS’s stock, with a simple moving average of -40.84% for the last 200 days.
Analysts’ Opinion of APLS
Many brokerage firms have already submitted their reports for APLS stocks, with Raymond James repeating the rating for APLS by listing it as a “Outperform.” The predicted price for APLS in the upcoming period, according to Raymond James is $52 based on the research report published on May 09, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see APLS reach a price target of $23. The rating they have provided for APLS stocks is “Neutral” according to the report published on May 09th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to APLS, setting the target price at $44 in the report published on April 29th of the current year.
APLS Trading at -18.57% from the 50-Day Moving Average
After a stumble in the market that brought APLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.72% of loss for the given period.
Volatility was left at 5.69%, however, over the last 30 days, the volatility rate increased by 6.81%, as shares sank -10.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.18% lower at present.
During the last 5 trading sessions, APLS fell by -9.62%, which changed the moving average for the period of 200-days by -55.56% in comparison to the 20-day moving average, which settled at $18.30. In addition, Apellis Pharmaceuticals Inc saw -45.85% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLS starting from Townsend Adam J., who proposed sale 220,961 shares at the price of $17.76 back on May 12 ’25. After this action, Townsend Adam J. now owns shares of Apellis Pharmaceuticals Inc, valued at $3,924,267 using the latest closing price.
Chopas James George, the VP/Chief Accounting Officer of Apellis Pharmaceuticals Inc, sale 183 shares at $24.82 during a trade that took place back on Mar 17 ’25, which means that Chopas James George is holding 47,955 shares at $4,543 based on the most recent closing price.
Stock Fundamentals for APLS
Current profitability levels for the company are sitting at:
- -0.24 for the present operating margin
- 0.83 for the gross margin
The net margin for Apellis Pharmaceuticals Inc stands at -0.29. The total capital return value is set at -0.3. Equity return is now at value -103.82, with -27.29 for asset returns.
Based on Apellis Pharmaceuticals Inc (APLS), the company’s capital structure generated 0.74 points at debt to capital in total, while cash flow to debt ratio is standing at -0.02. The debt to equity ratio resting at 2.86. The interest coverage ratio of the stock is -4.19.
Currently, EBITDA for the company is -154.53 million with net debt to EBITDA at -0.63. When we switch over and look at the enterprise to sales, we see a ratio of 2.94. The receivables turnover for the company is 3.17for trailing twelve months and the total asset turnover is 0.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.08.
Conclusion
To wrap up, the performance of Apellis Pharmaceuticals Inc (APLS) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
